Drug Profile
tgAAC 94
Alternative Names: rAAV2-TNFR:Fc; tgAAC11; tgAAC94; tgAAV-TNFR:Fc; TNFR:Fc gene therapyLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Targeted Genetics
- Developer Armata Pharmaceuticals
- Class Antirheumatics; Gene therapies
- Mechanism of Action Gene transference; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Periodontal disorders; Rheumatoid arthritis
Most Recent Events
- 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences